Letybo® (letibotulinumtoxinA‑wlbg) is a cutting‑edge neuromodulator recently FDA‑approved (Feb 29, 2024) as an effective alternative to Botox for smoothing moderate to severe glabellar lines (IAPAM).
It relaxes targeted facial muscles by blocking acetylcholine release, reducing dynamic wrinkles for a refreshed appearance (IAPAM).
Fast onset—patients often see results within 1–4 days
(Popsugar).
Lasts approximately 3–4 months (around 127 days in trials)
(IAPAM).
High‑purity formulation with controlled diffusion for natural
outcomes, reducing “frozen face” concerns (IAPAM).
Potential cost savings—studies suggest units may be 20 –
30% less expensive than Botox (Allure).
Indication: FDA-approved for moderate to severe glabellar
(frown) lines (IAPAM).
On-label use: single treatment spaced 3–4 months apart
(ABCS).
Safety Profile: Well‑tolerated—common mild side effects
include headaches, injection-site tenderness, and rare
ptosis (IAPAM).
Off-label possibilities: Can also address forehead lines,
crow’s feet, lip flips, masseters, and hyperhidrosis
(Popsugar).
Letybo gives providers a modern, high‑purity neurotoxin with rapid onset and natural results—plus speaks to
patient demand for cost-effective, results-driven options.
Disclaimer: All treatments should be administered by a qualified practitioner. Individual results may vary.
© 2025 Total Body Aesthetics. All Rights Reserved | Accessibility Statement | Privacy Policy | Sitemap
Powered by:
